TY - JOUR AU - Ciechanover, A. PY - 1998 DA - 1998// TI - The ubiquitin-proteasome pathway: on protein death and cell life JO - EMBO J VL - 17 UR - https://doi.org/10.1093/emboj/17.24.7151 DO - 10.1093/emboj/17.24.7151 ID - Ciechanover1998 ER - TY - JOUR AU - Ciechanover, A. AU - Schwartz, A. L. PY - 1998 DA - 1998// TI - The ubiquitin-proteasome pathway: the complexity and myriad functions of proteins death JO - Proc Natl Acad Sci U S A VL - 95 UR - https://doi.org/10.1073/pnas.95.6.2727 DO - 10.1073/pnas.95.6.2727 ID - Ciechanover1998 ER - TY - JOUR AU - Kisselev, A. F. AU - Akopian, T. N. AU - Castillo, V. AU - Goldberg, A. L. PY - 1999 DA - 1999// TI - Proteasome active sites allosterically regulate each other, suggesting a cyclical bite-chew mechanism for protein breakdown JO - Mol Cell VL - 4 UR - https://doi.org/10.1016/S1097-2765(00)80341-X DO - 10.1016/S1097-2765(00)80341-X ID - Kisselev1999 ER - TY - JOUR AU - Teicher, B. A. AU - Tomaszewski, J. E. PY - 2015 DA - 2015// TI - Proteasome inhibitors JO - Biochem Pharmacol VL - 96 UR - https://doi.org/10.1016/j.bcp.2015.04.008 DO - 10.1016/j.bcp.2015.04.008 ID - Teicher2015 ER - TY - JOUR AU - Adams, J. PY - 2004 DA - 2004// TI - The development of proteasome inhibitors as anticancer drugs JO - Cancer Cell VL - 5 UR - https://doi.org/10.1016/S1535-6108(04)00120-5 DO - 10.1016/S1535-6108(04)00120-5 ID - Adams2004 ER - TY - JOUR AU - Teicher, B. A. AU - Anderson, K. C. PY - 2015 DA - 2015// TI - CCR 20th anniversary commentary: In the beginning, there was PS-341 JO - Clin Cancer Res VL - 21 UR - https://doi.org/10.1158/1078-0432.CCR-14-2549 DO - 10.1158/1078-0432.CCR-14-2549 ID - Teicher2015 ER - TY - JOUR AU - Moreau, P. AU - Richardson, P. G. AU - Cavo, M. PY - 2012 DA - 2012// TI - Proteasome inhibitors in multiple myeloma: 10 years later JO - Blood VL - 120 UR - https://doi.org/10.1182/blood-2012-04-403733 DO - 10.1182/blood-2012-04-403733 ID - Moreau2012 ER - TY - JOUR AU - Allegra, A. AU - Alonci, A. AU - Gerace, D. PY - 2013 DA - 2013// TI - New orally proteasome inhibitors in multiple myeloma JO - Leuk Res VL - 38 UR - https://doi.org/10.1016/j.leukres.2013.10.018 DO - 10.1016/j.leukres.2013.10.018 ID - Allegra2013 ER - TY - JOUR AU - Andreu-Vieyra, C. AU - Berenson, J. R. PY - 2014 DA - 2014// TI - Carfilzomib in multiple myeloma JO - Expert Opin Biol Ther VL - 14 UR - https://doi.org/10.1517/14712598.2014.953050 DO - 10.1517/14712598.2014.953050 ID - Andreu-Vieyra2014 ER - TY - JOUR AU - Moreau, P. PY - 2014 DA - 2014// TI - The emerging role of carfilzomib combination therapy in the management of multiple myeloma JO - Expert Rev Hematol VL - 7 UR - https://doi.org/10.1586/17474086.2014.873699 DO - 10.1586/17474086.2014.873699 ID - Moreau2014 ER - TY - JOUR AU - Sugumar, D. AU - Keller, J. AU - Vij, R. PY - 2015 DA - 2015// TI - Targeted treatments for multiple myeloma: specific role of carfilzomib JO - Pharmgenomics Pers Med VL - 8 ID - Sugumar2015 ER - TY - JOUR AU - Richardson, P. G. AU - Moreau, P. AU - Laubach, J. P. PY - 2015 DA - 2015// TI - The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma JO - Future Oncol VL - 11 UR - https://doi.org/10.2217/fon.15.9 DO - 10.2217/fon.15.9 ID - Richardson2015 ER - TY - JOUR AU - Vij, R. AU - Savona, M. AU - Siegel, D. S. PY - 2014 DA - 2014// TI - Clinical profile of single-agent oprozomib in patients (pts) with multiple myeloma (MM): updated results from a multicenter, open-label, dose escalation phase 1b/2 study [abstract] JO - Blood VL - 124 ID - Vij2014 ER - TY - JOUR AU - Millward, M. AU - Price, T. AU - Townsend, A. PY - 2012 DA - 2012// TI - Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination JO - Invest New Drugs VL - 30 UR - https://doi.org/10.1007/s10637-011-9766-6 DO - 10.1007/s10637-011-9766-6 ID - Millward2012 ER - TY - JOUR AU - Sano, R. AU - Reed, J. C. PY - 2013 DA - 2013// TI - ER stress-induced cell death mechanisms JO - Biochim Biophys Acta VL - 1833 UR - https://doi.org/10.1016/j.bbamcr.2013.06.028 DO - 10.1016/j.bbamcr.2013.06.028 ID - Sano2013 ER - TY - JOUR AU - Mymrikov, E. V. AU - Seit-Nebi, A. S. AU - Gusev, N. B. PY - 2011 DA - 2011// TI - Large potentials of small heat shock proteins JO - Physiol Rev VL - 91 UR - https://doi.org/10.1152/physrev.00023.2010 DO - 10.1152/physrev.00023.2010 ID - Mymrikov2011 ER - TY - JOUR AU - Zhang, L. AU - Fok, J. H. AU - Davies, F. E. PY - 2014 DA - 2014// TI - Heat shock proteins in multiple myeloma JO - Oncotarget VL - 5 UR - https://doi.org/10.18632/oncotarget.1584 DO - 10.18632/oncotarget.1584 ID - Zhang2014 ER - TY - JOUR AU - Stokoe, D. AU - Engel, K. AU - Campbell, D. G. AU - Cohen, P. AU - Gaestel, M. PY - 1992 DA - 1992// TI - Identification of MAPKAP kinase 2 as a major enzyme responsible for the phosphorylation of the small mammalian heat shock proteins JO - FEBS Lett VL - 313 UR - https://doi.org/10.1016/0014-5793(92)81216-9 DO - 10.1016/0014-5793(92)81216-9 ID - Stokoe1992 ER - TY - JOUR AU - Rogalla, T. AU - Ehrnsperger, M. AU - Preville, X. PY - 1999 DA - 1999// TI - Regulation of Hsp27 oligomerization, chaperone function, and protective activity against oxidative stress/tumor necrosis factor α by phosphorylation JO - J Biol Chem VL - 274 UR - https://doi.org/10.1074/jbc.274.27.18947 DO - 10.1074/jbc.274.27.18947 ID - Rogalla1999 ER - TY - JOUR AU - Ashkenazi, A. PY - 2015 DA - 2015// TI - Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directions JO - J Clin Invest VL - 125 UR - https://doi.org/10.1172/JCI80420 DO - 10.1172/JCI80420 ID - Ashkenazi2015 ER - TY - JOUR AU - Fulda, S. AU - Vucic, D. PY - 2012 DA - 2012// TI - Targeting IAP proteins for therapeutic intervention in cancer JO - Nat Rev Drug Discov VL - 11 UR - https://doi.org/10.1038/nrd3627 DO - 10.1038/nrd3627 ID - Fulda2012 ER - TY - JOUR AU - Kane, R. C. AU - Bross, P. F. AU - Farrell, A. T. AU - Pazdur, R. PY - 2003 DA - 2003// TI - Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy JO - Oncologist VL - 8 UR - https://doi.org/10.1634/theoncologist.8-6-508 DO - 10.1634/theoncologist.8-6-508 ID - Kane2003 ER - TY - JOUR AU - Kane, R. C. AU - Farrell, A. T. AU - Sridhara, R. AU - Pazdur, R. PY - 2006 DA - 2006// TI - United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy JO - Clin Cancer Res VL - 12 UR - https://doi.org/10.1158/1078-0432.CCR-06-0170 DO - 10.1158/1078-0432.CCR-06-0170 ID - Kane2006 ER - TY - JOUR AU - Herndon, T. M. AU - Deisseroth, A. AU - Kaminskas, E. PY - 2013 DA - 2013// TI - U.S. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma JO - Clin Cancer Res VL - 19 UR - https://doi.org/10.1158/1078-0432.CCR-13-0755 DO - 10.1158/1078-0432.CCR-13-0755 ID - Herndon2013 ER - TY - JOUR AU - Nooka, A. AU - Gleason, C. AU - Casbourne, D. AU - Lonial, S. PY - 2013 DA - 2013// TI - Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib JO - Biologics VL - 7 ID - Nooka2013 ER - TY - JOUR AU - Siegel, D. AU - Martin, T. AU - Nooka, A. PY - 2013 DA - 2013// TI - Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies JO - Haematologica VL - 98 UR - https://doi.org/10.3324/haematol.2013.089334 DO - 10.3324/haematol.2013.089334 ID - Siegel2013 ER - TY - JOUR AU - Atrash, S. AU - Tullos, A. AU - Panozzo, S. PY - 2015 DA - 2015// TI - Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib JO - Blood Cancer J VL - 5 UR - https://doi.org/10.1038/bcj.2014.93 DO - 10.1038/bcj.2014.93 ID - Atrash2015 ER - TY - JOUR AU - Offidani, M. AU - Corvatta, L. AU - Caraffa, P. AU - Gentili, S. AU - Maracci, L. AU - Leoni, P. PY - 2014 DA - 2014// TI - An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma JO - Onco Targets Ther VL - 7 UR - https://doi.org/10.2147/OTT.S49187 DO - 10.2147/OTT.S49187 ID - Offidani2014 ER - TY - JOUR AU - Richardson, P. G. AU - Baz, R. AU - Wang, M. PY - 2014 DA - 2014// TI - Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients JO - Blood VL - 124 UR - https://doi.org/10.1182/blood-2014-01-548826 DO - 10.1182/blood-2014-01-548826 ID - Richardson2014 ER - TY - JOUR AU - Kumar, S. K. AU - Bensinger, W. I. AU - Zimmerman, T. M. PY - 2014 DA - 2014// TI - Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma JO - Blood VL - 124 UR - https://doi.org/10.1182/blood-2014-01-548941 DO - 10.1182/blood-2014-01-548941 ID - Kumar2014 ER - TY - JOUR AU - Kumar, S. K. AU - Berdeja, J. G. AU - Niesvizky, R. PY - 2014 DA - 2014// TI - Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study JO - Lancet Oncol VL - 15 UR - https://doi.org/10.1016/S1470-2045(14)71125-8 DO - 10.1016/S1470-2045(14)71125-8 ID - Kumar2014 ER - TY - JOUR AU - Kumar, S. K. AU - Berdeja, J. G. AU - Niesvizky, R. PY - 2014 DA - 2014// TI - Long-term ixazomib maintenance is tolerable and improves depth of response following ixazomib-lenalidomide-dexamethasone induction in patients (Pts) with previously untreated multiple myeloma (MM): phase 2 study results [abstract] JO - Blood VL - 124 UR - https://doi.org/10.1182/blood-2014-01-548941 DO - 10.1182/blood-2014-01-548941 ID - Kumar2014 ER - TY - JOUR AU - Handa, H. AU - Suzuki, K. AU - Chou, T. AU - Matsushima, T. PY - 2014 DA - 2014// TI - Phase 1 study of the investigational proteasome inhibitor ixazomib alone or in combination with lenalidomide–dexamethasone (Rd) in Japanese patients (Pts) with relapsed and/or refractory multiple myeloma (RRMM) [abstract] JO - Blood VL - 124 ID - Handa2014 ER - TY - JOUR AU - Moreau, P. PY - 2014 DA - 2014// TI - Oral therapy for multiple myeloma: ixazomib arriving soon [commentary] JO - Blood VL - 124 UR - https://doi.org/10.1182/blood-2014-06-581611 DO - 10.1182/blood-2014-06-581611 ID - Moreau2014 ER - TY - JOUR AU - Arendt, C. S. AU - Hochstrasser, M. PY - 1997 DA - 1997// TI - Identification of the yeast 20S proteasome catalytic centers and subunit interactions required for active-site formation JO - Proc Natl Acad Sci U S A VL - 94 UR - https://doi.org/10.1073/pnas.94.14.7156 DO - 10.1073/pnas.94.14.7156 ID - Arendt1997 ER - TY - JOUR AU - Heinemeyer, W. AU - Fischer, M. AU - Krimmer, T. AU - Stachon, U. AU - Wolf, D. H. PY - 1997 DA - 1997// TI - The active sites of the eukaryotic 20 S proteasome and their involvement in subunit precursor processing JO - J Biol Chem VL - 272 UR - https://doi.org/10.1074/jbc.272.40.25200 DO - 10.1074/jbc.272.40.25200 ID - Heinemeyer1997 ER - TY - JOUR AU - Swieten, P. F. AU - Samuel, E. AU - Hernández, R. O. PY - 2007 DA - 2007// TI - A cell-permeable inhibitor and activity-based probe for the caspase-like activity of the proteasome JO - Bioorg Med Chem Lett VL - 17 UR - https://doi.org/10.1016/j.bmcl.2007.03.092 DO - 10.1016/j.bmcl.2007.03.092 ID - Swieten2007 ER - TY - JOUR AU - Britton, M. AU - Lucas, M. M. AU - Downey, S. L. PY - 2009 DA - 2009// TI - Selective inhibitor of Proteasome’s caspase-like sites sensitizes cells to specific inhibition of chymotrypsin-like sites JO - Chem Biol VL - 16 UR - https://doi.org/10.1016/j.chembiol.2009.11.015 DO - 10.1016/j.chembiol.2009.11.015 ID - Britton2009 ER - TY - JOUR AU - Baldisserotto, A. AU - Ferretti, V. AU - Destro, F. PY - 2010 DA - 2010// TI - Alpha, beta-unsaturated N-acylpyrrole peptidyl derivatives: new proteasome inhibitors JO - J Med Chem VL - 53 UR - https://doi.org/10.1021/jm100122e DO - 10.1021/jm100122e ID - Baldisserotto2010 ER - TY - JOUR AU - Linden, W. A. AU - Willems, L. I. AU - Shabaneh, T. B. PY - 2012 DA - 2012// TI - Discovery of a potent and highly β1 specific proteasome inhibitor from a focused library of urea-containing peptide vinyl sulfones and peptide epoxyketones JO - Org Biomol Chem VL - 10 UR - https://doi.org/10.1039/C1OB06554H DO - 10.1039/C1OB06554H ID - Linden2012 ER - TY - JOUR AU - Parlati, F. AU - Lee, S. J. AU - Aujay, M. PY - 2009 DA - 2009// TI - Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome JO - Blood VL - 114 UR - https://doi.org/10.1182/blood-2009-05-223677 DO - 10.1182/blood-2009-05-223677 ID - Parlati2009 ER - TY - JOUR AU - Kupperman, E. AU - Lee, E. C. AU - Cao, Y. PY - 2010 DA - 2010// TI - Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer JO - Cancer Res VL - 70 UR - https://doi.org/10.1158/0008-5472.CAN-09-2766 DO - 10.1158/0008-5472.CAN-09-2766 ID - Kupperman2010 ER - TY - JOUR AU - Stewart, A. K. AU - Richardson, P. G. AU - San-Miguel, J. F. PY - 2009 DA - 2009// TI - How I treat multiple myeloma in younger patients JO - Blood VL - 114 UR - https://doi.org/10.1182/blood-2009-07-204651 DO - 10.1182/blood-2009-07-204651 ID - Stewart2009 ER - TY - JOUR AU - Andhavarapu, S. AU - Roy, V. PY - 2013 DA - 2013// TI - Immunomodulatory drugs in multiple myeloma JO - Expert Rev Hematol VL - 6 UR - https://doi.org/10.1586/ehm.12.62 DO - 10.1586/ehm.12.62 ID - Andhavarapu2013 ER - TY - JOUR AU - Cavo, M. AU - Tacchetti, P. AU - Patriarca, F. PY - 2010 DA - 2010// TI - Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study JO - Lancet VL - 376 UR - https://doi.org/10.1016/S0140-6736(10)61424-9 DO - 10.1016/S0140-6736(10)61424-9 ID - Cavo2010 ER - TY - JOUR AU - Rosinol, L. AU - Oriol, A. AU - Teruel, A. I. PY - 2012 DA - 2012// TI - Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study JO - Blood VL - 120 UR - https://doi.org/10.1182/blood-2012-02-408922 DO - 10.1182/blood-2012-02-408922 ID - Rosinol2012 ER - TY - JOUR AU - Richardson, P. G. AU - Weller, E. AU - Lonial, S. PY - 2010 DA - 2010// TI - Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma JO - Blood VL - 116 UR - https://doi.org/10.1182/blood-2010-02-268862 DO - 10.1182/blood-2010-02-268862 ID - Richardson2010 ER - TY - JOUR AU - Kumar, S. AU - Flinn, I. AU - Richardson, P. G. PY - 2012 DA - 2012// TI - Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma JO - Blood VL - 119 UR - https://doi.org/10.1182/blood-2011-11-395749 DO - 10.1182/blood-2011-11-395749 ID - Kumar2012 ER - TY - JOUR AU - Stewart, A. K. AU - Rajkumar, S. V. AU - Dimopoulos, M. A. PY - 2015 DA - 2015// TI - Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1411321 DO - 10.1056/NEJMoa1411321 ID - Stewart2015 ER - TY - JOUR AU - Fouquet, G. AU - Bories, C. AU - Guidez, S. PY - 2014 DA - 2014// TI - Pomalidomide for multiple myeloma JO - Expert Rev Hematol VL - 7 UR - https://doi.org/10.1586/17474086.2014.966074 DO - 10.1586/17474086.2014.966074 ID - Fouquet2014 ER - TY - JOUR AU - San Miguel, J. AU - Weisel, K. AU - Moreau, P. PY - 2013 DA - 2013// TI - Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial JO - Lancet Oncol VL - 14 UR - https://doi.org/10.1016/S1470-2045(13)70380-2 DO - 10.1016/S1470-2045(13)70380-2 ID - San Miguel2013 ER - TY - JOUR AU - Weisel, K. AU - Moreau, P. AU - Gibson, C. J. PY - 2015 DA - 2015// TI - Analyzing the relationship of response and survival in patients with refractory or relapsed and refractory multiple myeloma (RRMM) treated with pomalidomide plus low-dose dexamethasone (POM + LoDEX) in the MM-003 trial [abstract] JO - J Clin Oncol VL - 33 ID - Weisel2015 ER - TY - JOUR AU - Richardson, P. G. AU - Bensmaine, A. AU - Doerr, T. AU - Wang, J. AU - Zaki, M. H. PY - 2015 DA - 2015// TI - MM-007: A phase 3 trial comparing the efficacy and safety of pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX [PVD]) versus BORT and LoDEX (VD) in subjects with relapsed or refractory multiple myeloma (RRMM) [abstract] JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.60.1914 DO - 10.1200/JCO.2014.60.1914 ID - Richardson2015 ER - TY - STD TI - Stewart AK. Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma. Future Oncol. Prepublished on June 30, 2015, as doi:10.2217/fon.15.123 ID - ref54 ER -